Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEONEC: Neoadjuvant Chemotherapy in Localized Digestive Neuroendocrine Carcinomas
NCT04268121Phase 2Recruiting
- Sponsor
- GERCOR
- Start
- Jan 2021
- Primary completion
- Jan 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, carboplatin, etoposide in digestive neuroendocrine carcinoma (GEP-NEC), sponsored by GERCOR. Started Jan 2021; status: recruiting.
02
Drugs
cisplatincarboplatinetoposide
03
Conditions
digestive neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on NCT04268121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268121.